{"ctNumber":"2024-514783-78-00","ctStatus":"Authorised","startDateEU":"2024-10-29","decisionDate":"2024-10-29T09:52:54.845","publishDate":"2026-08-22T03:30:57.82943289","ctPublicStatusCode":5,"authorizedApplication":{"authorizedPartI":{"id":60094,"rowSubjectCount":0,"products":[{"id":244679,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Softisan 378","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Softisan 378","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"},{"id":244680,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11647816","productPharmForm":"CAPSULE","euMpNumber":"PRD11647816","prodAuthStatus":1,"prodName":"Cannabidiol","pharmForm":"CAPSULE","activeSubstanceName":"CANNABIDIOL","euSubstNumber":"SUB26600","nameOrg":"UNIVERSITAIR MEDISCH CENTRUM UTRECHT","productSubstances":[{"productPk":"11647816","substancePk":"337822","nameOrg":"UNIVERSITAIR MEDISCH CENTRUM UTRECHT","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"CANNABIDIOL","substanceEvCode":"SUB26600","synonyms":["CBD"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"600","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"600","maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Cannabinoids","evCode":"PRD11647816","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"Cannabidiol","jsonActiveSubstanceNames":"cannabidiol","pharmaceuticalFormDisplay":"CAPSULE"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms","fullTitleTranslations":[{"id":4201012,"uuid":"08c35d36-ee34-4d8e-a533-f7b9c8591b33","attributeTranslation":"BOOSTCAMP: Versterking van het endocannabinoïde systeem voorafgaand aan de behandeling van angstsymptomen","language":37,"languageDescription":"Dutch (Netherlands)"}],"publicTitle":"BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms","publicTitleTranslations":[{"id":4201017,"uuid":"adf58472-7523-4c9d-a4be-2728ed0155ce","attributeTranslation":"BOOSTCAMP: Versterking van het endocannabinoïde systeem voorafgaand aan de behandeling van angstsymptomen","language":37,"languageDescription":"Dutch (Netherlands)"}],"shortTitle":"20U-0014","secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"This study investigates the effects and safety of CBD in a clinical population","trialCategoryId":52136},"medicalCondition":{"partIMedicalConditions":[{"id":60057,"medicalCondition":"psychological disorders: PTSD; Anxiety disorders","medicalConditionTranslations":[{"id":4200998,"uuid":"494e62ef-c229-4b11-afa0-e4de18620a3b","attributeTranslation":"psychologische stoornissen: PTSS en angststoornissen","language":37,"languageDescription":"Dutch (Netherlands)"}],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"5","trialScopeId":173026},{"code":"3","trialScopeId":173027}],"mainObjective":"to examine the effects of a 2-week administration of Cannabidiol (CBD) in alleviating anxiety symptoms before anxiety or PTSD treatments in Dutch uniformed personnel","mainObjectiveTranslations":[{"id":4201016,"uuid":"14c59cde-a0e7-4daf-98a3-f4f365076218","attributeTranslation":"het effect van een tweeweekse toediening cannabidiol (CBD) in het verlichten van angstsymptomen voor de start van een angst- of traumabehandeling in Nederlands geüniformeerd personeel.","language":37,"languageDescription":"Dutch (Netherlands)"}],"secondaryObjectives":[{"id":194338,"number":1,"secondaryObjective":"1. Examine the effects of fear extinction and  consolidation of a fear conditioning paradigm 2. study the effect of CBD on stress regulation 3. Examine the effects of CBD on sleep quality","secondaryObjectiveTranslations":[{"id":4201018,"uuid":"5d922d4f-4c17-4def-b576-846adb2b3423","attributeTranslation":"1. onderzoeken wat het effect van CBD is op het aan- en afleren van angst\n2. onderzoeken wat het effect van CBD is op het reguleren van stress\n3. onderzoeken wat het effect van CBD is op de slaapkwaliteit","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":377470,"number":1,"principalInclusionCriteria":"Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans.","principalInclusionCriteriaTranslations":[{"id":4201013,"uuid":"7074c646-844d-4053-a643-225bfc26c890","attributeTranslation":"Nederlands geüniformeerd personeel, waaronder (voormalig) politie-agenten, brandweermensen, ambulancebroeders, militairen en veteranen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":377471,"number":2,"principalInclusionCriteria":"Age between 18-65","principalInclusionCriteriaTranslations":[{"id":4201014,"uuid":"b738754c-3b4d-48e3-b4f2-fb98ac93722c","attributeTranslation":"Leeftijd tussen de 18-65 jaar","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":377472,"number":3,"principalInclusionCriteria":"Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)","principalInclusionCriteriaTranslations":[{"id":4201015,"uuid":"719bbe04-d438-459b-a1d0-5760b7bd18d7","attributeTranslation":"Aan het wachten op behandeling voor trauma- of stressorgerelateerde stoornissen of een angststoornis, zoals bepaalde door de MINI PLUS psychiatrisch interview","language":37,"languageDescription":"Dutch (Netherlands)"}]}],"principalExclusionCriteria":[{"id":650896,"number":1,"principalExclusionCriteria":"Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)","principalExclusionCriteriaTranslations":[{"id":4201003,"uuid":"77171a57-4b96-4485-b7f5-55eac116a9a3","attributeTranslation":"Ernstige comorbiditeit (ernstige major depressie, bipolaire stoornis of psychose)","language":18,"languageDescription":"Dutch"}]},{"id":650897,"number":2,"principalExclusionCriteria":"Alcohol and/or drug dependence","principalExclusionCriteriaTranslations":[{"id":4201004,"uuid":"c104cb99-d7f4-4007-97b3-8036134bc724","attributeTranslation":"alcohol- of drugsverslaving","language":18,"languageDescription":"Dutch"}]},{"id":650898,"number":3,"principalExclusionCriteria":"Inability to adequately read or speak Dutch","principalExclusionCriteriaTranslations":[{"id":4201005,"uuid":"4b0e7e18-6ae4-47a9-9d09-75b504a2b4b9","attributeTranslation":"onvermogen om nederlands te schrijven of te spreken","language":18,"languageDescription":"Dutch"}]},{"id":650899,"number":4,"principalExclusionCriteria":"(a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities","principalExclusionCriteriaTranslations":[{"id":4201006,"uuid":"157da7e7-f2f6-493c-92b0-159247e5e9ee","attributeTranslation":"(een geschiedenis van) epilepsie of hersenschade, hart-, nier- of leverafwijkingen","language":18,"languageDescription":"Dutch"}]},{"id":650900,"number":5,"principalExclusionCriteria":"(a history of) allergies to medication (adverse reactions or rash)","principalExclusionCriteriaTranslations":[{"id":4201007,"uuid":"3350ad0a-3027-4e4b-8def-02046c2341d7","attributeTranslation":"(een geschiedenis van) allergieën op medicatie ( bijwerkingen of uitslag)","language":18,"languageDescription":"Dutch"}]},{"id":650901,"number":6,"principalExclusionCriteria":"Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)","principalExclusionCriteriaTranslations":[{"id":4201008,"uuid":"5800efb3-1db0-49a2-bc4b-449a85bc853e","attributeTranslation":"Het gebruik van medicatie waarvan bekend is dat er interacties zijn met CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)","language":18,"languageDescription":"Dutch"}]},{"id":650902,"number":7,"principalExclusionCriteria":"Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening.","principalExclusionCriteriaTranslations":[{"id":4201009,"uuid":"675f2219-db7d-4320-ae89-96c5b5130217","attributeTranslation":"het gebruik van cannabis, synthetisch cannabinoïde, cannabinoïde analoog of een ander CBD of THC-bevattend product binnen 30 dagen na screening","language":18,"languageDescription":"Dutch"}]},{"id":650903,"number":8,"principalExclusionCriteria":"Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD","principalExclusionCriteriaTranslations":[{"id":4201010,"uuid":"c99a69e8-1a43-4f3d-93c4-174770fb2bbf","attributeTranslation":"Individuen die gediagnosticeerd zijn met darm-, lever- of nierstoornissen die de absorptie of afbraak van CBD in de weg staan","language":18,"languageDescription":"Dutch"}]},{"id":650904,"number":9,"principalExclusionCriteria":"For women: pregnant, a wish to become pregnant, or nursing","principalExclusionCriteriaTranslations":[{"id":4201011,"uuid":"cf4cd8dc-1503-4142-9ea7-2d0ff3c5090e","attributeTranslation":"Voor vrouwen: (de wens om) zwanger zijn, borstvoeding geven","language":18,"languageDescription":"Dutch"}]}]},"endPoint":{"primaryEndPoints":[{"id":436735,"number":1,"endPoint":"Beck’s anxiety index between the first and second week.","isPrimary":true,"endPointTranslations":[{"id":4200999,"uuid":"82e1cd8a-0327-4172-ba67-8fed86ec549d","attributeTranslation":"Beck’s anxiety index tussen de eerste en tweede week van het onderzoek","language":18,"languageDescription":"Dutch"}]}],"secondaryEndPoints":[{"id":436736,"number":1,"endPoint":"Effect of CBD on Fear extinction (i.e. physiological responses and subjective fear)","isPrimary":false,"endPointTranslations":[{"id":4201000,"uuid":"92cd9828-d37a-46ec-90fc-8b0a5b7f1b7a","attributeTranslation":"Effect van CBD op angstextinctie (zoals fysiologische reacties en subjectieve angst)","language":18,"languageDescription":"Dutch"}]},{"id":436737,"number":2,"endPoint":"Effect of CBD on stress regulation with the Maastricht Acute Stress Test (MAST; i.e. Subjective stress, physiological responses, alpha-amylase and cortisol)","isPrimary":false,"endPointTranslations":[{"id":4201001,"uuid":"5913c10b-af28-4007-9e49-7ccd5562b368","attributeTranslation":"Het effect van CBD op stress regulatie met de Maastricht Acute Stress Test (MAST; Subjectieve stress, fysiologische responses, alpha-amylase en cortisol)","language":18,"languageDescription":"Dutch"}]},{"id":436738,"number":3,"endPoint":"Effect of CBD on Sleep quality (i.e. questionnaires and a sleep watch)","isPrimary":false,"endPointTranslations":[{"id":4201002,"uuid":"29d19868-ff69-4295-a1c2-36e8988d934a","attributeTranslation":"Het effect van CBD op slaapkwaliteit (met vragenlijsten en een slaaphorloge)","language":18,"languageDescription":"Dutch"}]}]},"trialDuration":{"estimatedEndDate":"2025-12-31","estimatedRecruitmentStartDate":"2024-07-01"},"sourceOfMonetarySupport":[{"id":42299,"organisationName":"Brain Research and Innovation Center, Ministry of Defense"}],"populationOfTrialSubjects":{"ageRanges":[{"id":162192,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-29","conclusionDate":"2024-10-29","therapeuticAreas":[{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}],"medicalConditions":[{"id":60057,"medicalCondition":"psychological disorders: PTSD; Anxiety disorders","isConditionRareDisease":false}],"sponsors":[{"id":63582,"primary":true,"publicContacts":[{"id":188699,"type":"Public","functionalName":"Remco van Zijderveld","functionalEmailAddress":"r.vanzijderveld-2@umcutrecht.nl","telephone":"+31302502507","organisation":{"id":492813,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Utrecht","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008351","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":188700,"type":"Scientific","functionalName":"Remco van Zijderveld","functionalEmailAddress":"r.vanzijderveld-2@umcutrecht.nl","telephone":"+31302502507","organisation":{"id":492813,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Utrecht","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008351","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":492813,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Utrecht","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008351","organisationLocationStatus":"Active"},"addresses":[{"id":460502,"organisation":{"id":492813,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Utrecht","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008351","organisationLocationStatus":"Active"},"address":{"addressId":493601,"oneLine":"Heidelberglaan 100","addressLine1":"Heidelberglaan 100","addressLine2":"","addressLine3":"","addressLine4":"","city":"Utrecht","postcode":"3584 CX","country":2029,"countryName":"Netherlands"},"isBusinessKeyValidated":true,"businessKey":"ORG-100008351"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This study investigates the effects and safety of CBD in a clinical population","partOneTherapeuticAreas":[{"id":664357,"therapeuticArea":{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}}],"productRoleGroupInfos":[{"id":189112,"comments":"Softisan 378","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":244679,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Softisan 378","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Softisan 378","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"}]},{"id":189113,"comments":"Cannabidiol","productRoleCode":"1","productRoleName":"Test","products":[{"id":244680,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11647816","productPharmForm":"CAPSULE","euMpNumber":"PRD11647816","prodAuthStatus":1,"prodName":"Cannabidiol","pharmForm":"CAPSULE","activeSubstanceName":"CANNABIDIOL","euSubstNumber":"SUB26600","nameOrg":"UNIVERSITAIR MEDISCH CENTRUM UTRECHT","productSubstances":[{"productPk":"11647816","substancePk":"337822","nameOrg":"UNIVERSITAIR MEDISCH CENTRUM UTRECHT","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"CANNABIDIOL","substanceEvCode":"SUB26600","synonyms":["CBD"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"600","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"600","maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Cannabinoids","evCode":"PRD11647816","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"Cannabidiol","jsonActiveSubstanceNames":"cannabidiol","pharmaceuticalFormDisplay":"CAPSULE"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":149870,"mscId":32589,"mscInfo":{"id":32589,"clinicalTrialId":15684,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2024-10-22","toDate":"2024-10-22","isProposedRms":true,"countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2024-10-29","trialStatus":"Authorised","trialPeriod":[{"id":71383,"trialStartDate":"2024-10-29","fromDate":"2025-12-18"},{"id":71384,"trialStartDate":"2024-10-29","fromDate":"2025-12-18"}],"trialRecruitmentPeriod":[{"id":104783,"recruitmentStartDate":"2024-10-29","fromDate":"2026-03-25"},{"id":104784,"recruitmentStartDate":"2024-10-29","fromDate":"2026-03-25"},{"id":113476,"recruitmentStartDate":"2024-10-29","recruitmentEndDate":"2026-06-09","fromDate":"2026-06-09"},{"id":120276,"recruitmentStartDate":"2024-10-29","recruitmentEndDate":"2026-06-23","fromDate":"2026-08-21"},{"id":120277,"recruitmentStartDate":"2024-10-29","recruitmentEndDate":"2026-06-23","fromDate":"2026-08-21"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":112044,"trialStartDate":"2024-10-29","fromDate":"2025-12-18"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-29","recruitmentEndDate":"2026-06-23"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":59090,"mscId":32589,"trialStatus":"Authorised","trialStatusDate":"2024-10-29T09:52:54.458"},{"id":55546,"mscId":32589,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-07T14:09:57.384"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-29","decision":"authorized","decisionDate":"2024-10-29"},"decisionDate":"2024-10-29","recruitmentSubjectCount":82,"trialSites":[{"id":975479,"organisationAddressInfo":{"id":603921,"organisation":{"id":636804,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Utrecht","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008351","organisationLocationStatus":"Active"},"address":{"addressId":652179,"oneLine":"Heidelberglaan 100","addressLine1":"Heidelberglaan 100","addressLine2":"","addressLine3":"","addressLine4":"","city":"Utrecht","postcode":"3584 CX","country":2029,"countryName":"Netherlands"},"phone":"0302502117","email":"A.d.DeWeijer@umcutrecht.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100008351"},"personInfo":{"id":1089131,"firstName":"Antoin","lastName":"de Weijer","telephone":"0302502117","email":"A.d.DeWeijer@umcutrecht.nl","title":"1"},"departmentName":"Brain"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":26924,"type":"INITIAL","status":"Authorised","ctNumber":"2024-514783-78-00","trialStatus":"Authorised","submissionDate":"2024-10-07","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-29"},"partIIInfo":[{"id":149870,"mscId":32589,"mscInfo":{"id":32589,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-29","decision":"authorized","decisionDate":"2024-10-29","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-10-29"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-10-29","ctMSCsByApplication":[{"id":32589,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":44022,"applicationId":26924,"mscId":32589,"mscName":"Netherlands","decisionDate":"2024-10-29T09:52:54.845","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":149870,"part1Id":60094,"applicationType":"INITIAL","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Netherlands","mscId":32589,"firstDecisionDate":"2024-10-29T09:52:54.845","lastDecisionDate":"2024-10-29T09:52:54.845","mscPublicStatusCode":5}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2020-003739-62"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":32589,"mscName":"Netherlands","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-29"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-10-29"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-06-23"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol 2024-514783-78-00_For_Publication","uuid":"5955ee69-028b-48d8-a088-03d0b522f77e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":60094,"manualVersion":"11","systemVersion":"1"},{"title":"K1_blank document","uuid":"2c793d09-fdb3-41b0-b945-1f75bd83dfe1","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":149870,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_2024514783-78","uuid":"be8f82ac-8faf-4ce4-83f5-582f62b80cb6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":149870,"manualVersion":"10","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}